Eelemene hydrogel as well as preparation method and application thereof
Through the nano-delivery technology of elene hydrogel, the problem that existing elene drugs are difficult to achieve local legacy and targeted distribution is solved, effective controlled release of tumor postoperative sites is achieved, and tumor recurrence and metastasis is inhibited. Significantly improves the therapeutic effect.
Patent Information
- Application Number
- CN202411171512.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-23
- Publication Date
- 2024-11-26
AI Technical Summary
Existing eleanene drugs are difficult to achieve local legacy and targeted distribution, resulting in a high rate of postoperative tumor recurrence and metastasis.
Develop an elene hydrogel that mixes elene with a hydrogel matrix evenly through nanodelivery carriers such as liposomes or polymer nanoparticles, and controls the release of elene, directly acts on tumors. Postoperative site.
By promoting tumor cell apoptosis and enhancing anti-tumor immune response, it effectively inhibits tumor recurrence and metastasis after surgery, significantly improving the therapeutic effect.
Smart Images

Figure CN119015215A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of medicines, and in particular relates to an elemene hydrogel and a preparation method and application thereof. Background Art
[0002] Currently, surgery remains the main treatment for solid tumors. However, even with complete local resection of the tumor entity, the postoperative tumor recurrence rate is still as high as one-third, and the mortality rate is very high. The postoperative wound healing process activates some signaling pathways involving nerves, inflammation, and angiogenesis, and the activation of these signaling pathways further promotes the growth and metastasis of cancer. More and more studies have also shown that some perioperative interventions can also promote the aggravation of existing metastasis and even further growth of residual tumor cells, leading to local cancer recurrence or distant metastasis of cancer cells, causing postoperative cancer recurrence and metastasis.
[0003] Elemene (ELE) is a broad-spectrum anticancer compound containing β-elemene, γ-elemene, δ-elemene and other ingredients, which are derived from traditional Chinese medicines such as Curcuma zedoaria and Curcuma longa. Elemene exerts its anticancer effects by regulating multiple signaling pathways and targets, inducing cancer cell apoptosis and ferroptosis, blocking epithelial-mesenchymal transition and inhibiting cancer cell metastasis. In addition, elemene can activate anti-tumor immunity and regulate CD8 + T and CD4 + The activity of T immune cells and the promotion of M1 polarization of macrophages. These physiological effects of elemene make it show great application potential in the treatment of brain glioma, lung cancer, liver cancer, bone metastasis, breast cancer and other diseases. However, the current elemene drug dosage forms mainly include oral preparations and injections, which make it difficult to achieve local retention and targeted distribution of drug molecules. Summary of the invention
[0004] The purpose of the present invention is to provide an elemene hydrogel and a preparation method and application thereof. The elemene hydrogel provided by the present invention can directly act on the postoperative site of the tumor to achieve the controlled release of elemene.
[0005] In order to achieve the purpose of the present invention, the present invention provides the following technical solutions:
[0006] The invention provides an elemene hydrogel, comprising a hydrogel matrix and a drug-loaded nanoformulation distributed in the hydrogel matrix; the drug-loaded nanoformulation comprises a nano delivery carrier and an effective ingredient loaded in the nano delivery carrier; the effective ingredient comprises β-elemene, an elemene raw material drug or a drug pair containing elemene.
[0007] Preferably, the drug pair containing elemene includes elemene-cabazitaxel, elemene-oxaliplatin, elemene-sorafenib or elemene-cisplatin.
[0008] Preferably, the nano-delivery carrier comprises a liposome, a lipid nanoparticle, a polymer nanoparticle, a lipid polymer nanoparticle, a nanoemulsion, a mesoporous silica or a nanosheet;
[0009] The raw materials for preparing the lipid polymer nanoparticles include lipid raw materials and polymer raw materials; the lipid raw materials of the lipid polymer nanoparticles include 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-polyethylene glycol or dimyristoylglycerol-polyethylene glycol, and the polymer raw materials include polylactic acid-co-glycolic acid, polylactic acid or polyacetic acid lactone;
[0010] The nanosheets include stanene nanosheets or germanene nanosheets.
[0011] Preferably, the raw materials for preparing the hydrogel matrix include gel matrix materials; the gel matrix materials include one or more of polyethylene glycol, methacrylic acid, hyaluronic acid-dopamine grafts, chitosan, alginate and silk fibroin;
[0012] The grafting degree of the hyaluronic acid-dopamine graft is 30-70%.
[0013] Preferably, the particle size of the drug-loaded nanoformulation is 20 to 500 nm;
[0014] The concentration of the drug-loaded nanometer preparation in the elemene hydrogel is 5-20 mg / mL, the concentration of the effective component is 1-4 mg / mL, and the water content is 92-98%.
[0015] The present invention also provides a method for preparing the elemene hydrogel described in the above technical solution, comprising the following steps:
[0016] Constructing a drug-loaded nanoformulation, wherein the drug-loaded nanoformulation comprises a nano delivery carrier and an effective ingredient loaded in the nano delivery carrier;
[0017] The drug-loaded nanoformulation and the gel matrix material are mixed to obtain the elemene hydrogel.
[0018] Preferably, when the nano delivery carrier is a lipid polymer nanoparticle, the method for preparing the drug-loaded nano preparation comprises the following steps:
[0019] The active ingredient, lipid raw material, polymer raw material, organic solvent and water are mixed to obtain the drug-loaded nano preparation.
[0020] Preferably, the preparation method of the hyaluronic acid-dopamine graft comprises the following steps:
[0021] Hyaluronic acid, dopamine, a grafting catalyst and water are mixed, and a grafting reaction is carried out in an acidic environment to obtain the hyaluronic acid-dopamine grafted product.
[0022] The present invention also provides the use of the elemene hydrogel described in the above technical solution or the elemene hydrogel obtained by the preparation method described in the above technical solution in preparing a preparation for treating postoperative tumor recurrence or metastasis.
[0023] Preferably, the tumor comprises lung cancer, brain cancer, liver cancer, breast cancer, stomach cancer, esophageal cancer or pancreatic cancer.
[0024] The present invention provides an elemene hydrogel, comprising a hydrogel matrix and a drug-loaded nanoformulation distributed in the hydrogel matrix; the drug-loaded nanoformulation comprises a nano delivery carrier and an effective ingredient loaded in the nano delivery carrier; the effective ingredient comprises β-elemene, elemene API or a drug pair containing elemene. The elemene hydrogel provided by the present invention uses a nano delivery carrier as a carrier of elemene, which can improve the hydrophobicity of elemene so that it can be evenly mixed with the hydrogel matrix. Furthermore, the drug-loaded nanoformulation is loaded with the hydrogel to control the release of elemene nanomedicine. The elemene hydrogel controls the release of elemene at the site of tumor surgery. On the one hand, the elemene nanomedicine exerts a tumor cell killing effect by promoting tumor cell apoptosis, and on the other hand, by increasing the CD8 + T cells and CD4 + T enhances anti-tumor immunity and promotes the polarization of tumor-associated macrophages M2 to M1 phenotype, thereby effectively inhibiting tumor recurrence and metastasis after surgery. BRIEF DESCRIPTION OF THE DRAWINGS
[0025] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative labor.
[0026] Figure 1 : are characterization diagrams of elemene nanoparticles obtained in Example 1, wherein A is a physical diagram of the dispersion of elemene nanoparticle solution, B is a diagram of particle size test data of elemene nanoparticles, C is a diagram of Zeta potential test of elemene nanoparticles, D is a SEM imaging diagram of elemene nanoparticles, E is an infrared spectrum diagram of each substance involved in the example, F is a diagram of particle size and polydispersity index of elemene nanoparticles at 37° C., and G is a diagram of particle size and polydispersity index of elemene nanoparticles at 4° C.;
[0027] Figure 2: is a characterization diagram of the elemene hydrogel obtained in Example 1, wherein A is a schematic diagram of the preparation of the elemene hydrogel, B is a nuclear magnetic resonance hydrogen spectrum of hyaluronic acid, dopamine and hyaluronic acid-dopamine grafts, C is a physical image of the elemene hydrogel, D is a characterization diagram of the bioadhesion of the elemene hydrogel, E is a SEM imaging diagram of the elemene hydrogel, F is a characterization diagram of the self-healing properties of the elemene hydrogel, G is a swelling rate test diagram of the elemene hydrogel, H is a storage modulus and loss modulus diagram of the elemene hydrogel at different angular frequencies, I is a storage modulus and loss modulus diagram of the elemene hydrogel at different strains, and J is a cyclic storage modulus and loss modulus value diagram of the elemene hydrogel under alternating strain scanning;
[0028] Figure 3 Figures are in vivo and in vitro release test diagrams of elemene hydrogel, wherein A is a schematic diagram of the release mode of elemene hydrogel and elemene nanoparticle dispersion, B is a schematic diagram of the release kinetics of elemene hydrogels at three different concentrations, C is a schematic diagram of the release behavior of elemene hydrogel and elemene nanoparticle dispersion at the mouse level, D is a fluorescent IVIS imaging diagram at different time points after implanting elemene hydrogel and injecting elemene nanoparticle dispersion into mice using DiR as a fluorescent marker, E is a quantitative data diagram of the residual fluorescence percentage of Figure D after normalization with the fluorescence intensity at the initial time, and F is a fluorescent imaging diagram of the surrounding tissue 20 days after implantation of elemene hydrogel and elemene nanoparticle dispersion;
[0029] Figure 4 Figure 1 is a test diagram of the effect of elemene hydrogel in inhibiting postoperative recurrence and metastasis of breast cancer, wherein A is a schematic diagram of the surgical process of elemene hydrogel in inhibiting tumor recurrence and metastasis, B is a timeline diagram of the experiment of inhibiting tumor recurrence and metastasis, C is a bioluminescence imaging diagram of 4T1-Luc tumor-bearing mice after different treatments, D is a bioluminescence quantitative data diagram of Figure C, E is a diagram of the changes in tumor volume of mice in each group after different treatments, F is a representative photo of mouse lung tissue after different treatments and the corresponding H&E staining image diagram, G is a representative immunohistochemical staining image diagram of E-cadherin in residual tumor tissue after different treatments, and H is a diagram of the changes in body weight of mice in each treatment group;
[0030] Figure 5 This is a test diagram of the effect of elemene hydrogel in activating anti-tumor immune response, where A is the CD3 + CD8 + Representative flow cytometry analysis of T cells, B is CD45 + CD3 + CD8 + Quantitative graph of the percentage of cells, C is the CD45 + CD3 + CD8 +Quantitative graph of the percentage of cells, D is the CD3 + CD4 + Representative flow cytometry analysis of T cells, E is CD45 + CD3 + CD4 + Quantitative graph of the percentage of cells, F is the CD45 + CD3 + CD4 + Quantitative graph of the percentage of cells, G is the CD25 + Foxp3 + Representative flow cytometry analysis of T cells, H is CD4 + CD25 + Foxp3 + Quantitative graph of the percentage of T cells, I is CD25 in tumor cells + Foxp3 + Quantitative graph of the percentage of cells, J is the immunofluorescence image of the residual tumor tissue in different treatment groups. Red: macrophages stained with F4 / 80 antibody; yellow: M1 macrophages stained with CD80 antibody; blue: cell nuclei stained with DAPI. The scale is 40 μm. The secretion levels of inflammatory factors TNF-α (K), IL-6 (L), and IFN-γ (M) in the serum of mice in each group;
[0031] Figure 6 Figure 1 is a diagram of the in vivo safety evaluation of elemene hydrogel, wherein A is a physical comparison diagram of the hemolysis of elemene hydrogel, B is a diagram of the hemolysis test results of elemene hydrogel, C is a schematic diagram of extracting elemene hydrogel extract, D is a diagram of cell viability after co-incubation of L929 cells with different concentrations of hydrogel extracts for 24 hours, E is a diagram of the changes in various blood biochemical indicators in blood samples of mice treated with elemene hydrogel for 30 days (with untreated healthy mice as the control group), and F is a H&E staining diagram of the five internal organs of healthy mice and mice treated with elemene hydrogel for 30 days;
[0032] Figure 7 Schematic diagram of the release kinetics of elemene nanoformulation controlled by hydrogel, wherein A is a schematic diagram of the release kinetics of elemene hydrogel and elemene nano solution, and B is a diagram showing the mechanism of hydrogel with controlled elemene nanodrug release kinetics inhibiting postoperative recurrence and metastasis of breast cancer. DETAILED DESCRIPTION
[0033] The invention provides an elemene hydrogel, comprising a hydrogel matrix and a drug-loaded nanoformulation distributed in the hydrogel matrix; the drug-loaded nanoformulation comprises a nano delivery carrier and an effective ingredient loaded in the nano delivery carrier; the effective ingredient comprises β-elemene, an elemene raw material drug or a drug pair containing elemene.
[0034] In the present invention, unless otherwise specified, all preparation raw materials are preferably commercially available products well known to those skilled in the art.
[0035] In the present invention, the active ingredient includes β-elemene, elemene API or a drug pair containing elemene, preferably β-elemene or a drug pair containing elemene, more preferably β-elemene; the drug pair containing elemene preferably includes elemene-cabazitaxel, elemene-oxaliplatin, elemene-sorafenib or elemene-cisplatin, more preferably elemene-cabazitaxel or elemene-oxaliplatin.
[0036] In the present invention, the nano delivery carrier preferably includes liposomes, lipid nanoparticles, polymer nanoparticles, lipid polymer nanoparticles, nanoemulsions, mesoporous silica or nanosheets, more preferably liposomes, polymer nanoparticles, lipid polymer nanoparticles or nanosheets, and most preferably liposomes or lipid polymer nanoparticles; the raw materials for preparing the lipid polymer nanoparticles include lipid raw materials and polymer raw materials; the lipid raw materials of the lipid polymer nanoparticles preferably include 1,2-distearoyl-sn-glycerol-3-phosphoethanolamine-polyethylene glycol or dimyristoylglycerol-polyethylene glycol, more preferably 1,2-distearoyl-sn-glycerol-3-phosphoethanolamine-polyethylene glycol, the polymer raw materials preferably include polylactic acid-glycolic acid copolymer, polylactic acid or polyacetic acid lactone, more preferably polylactic acid-glycolic acid copolymer; the nanosheets preferably include stanene nanosheets or germanene nanosheets.
[0037] In the present invention, the raw materials for preparing the hydrogel matrix preferably include gel matrix material and water; the gel matrix material preferably includes one or more of polyethylene glycol, methacrylic acid, hyaluronic acid-dopamine grafts, chitosan, alginate and silk fibroin, and more preferably one or more of polyethylene glycol, methacrylic acid, hyaluronic acid-dopamine grafts or chitosan; the grafting degree of the hyaluronic acid-dopamine graft is preferably 30-70%, more preferably 40-65%, and most preferably 65%; the mass percentage of the gel matrix material in the hydrogel matrix is preferably 1-7.5%, and more preferably 2-4%.
[0038] In the present invention, the particle size of the drug-loaded nanoformulation is preferably 20 to 500 nm, more preferably 100 to 300 nm; the encapsulation rate of the active ingredient is preferably 60% or more, more preferably 80 to 85%; the polydispersity coefficient of the drug-loaded nanoformulation is preferably 0.3 or less, more preferably 0.2 or less; the concentration of the drug-loaded nanoformulation in the elemene hydrogel is preferably 5 to 20 mg / mL, more preferably 7.5 to 10 mg / mL; the concentration of elemene is preferably 1 to 4 mg / mL, more preferably 1.5 to 2 mg / mL; the water content is preferably 92 to 98%, more preferably 94 to 97.5%.
[0039] The elemene hydrogel provided by the present invention adopts a nano delivery carrier as a carrier of the elemene effective ingredient, which can improve the hydrophobicity of elemene so as to be uniformly mixed with the hydrogel matrix. Furthermore, the hydrogel is loaded with a drug-loaded nano preparation to control the release of elemene nano drugs. The elemene hydrogel controls the release of elemene at the site of tumor surgery. On the one hand, the elemene nano drug plays a tumor cell killing effect by promoting tumor cell apoptosis, and on the other hand, it increases the expression of CD8 + T cells and CD4 + T enhances anti-tumor immunity and promotes the polarization of tumor-associated macrophages M2 to M1 phenotype, thereby effectively inhibiting tumor recurrence and metastasis after surgery.
[0040] The present invention also provides a method for preparing the elemene hydrogel described in the above technical solution, comprising the following steps:
[0041] Constructing a drug-loaded nanoformulation, wherein the drug-loaded nanoformulation comprises a nano delivery carrier and an effective ingredient loaded in the nano delivery carrier;
[0042] The drug-loaded nanoformulation and the gel matrix material are mixed to obtain the elemene hydrogel.
[0043] In the present invention, the active ingredient is preferably encapsulated in the nano delivery carrier; the present invention has no special limitation on the process of constructing the drug-loaded nano preparation, and the active ingredient can be loaded into the nano delivery carrier using a process well known to those skilled in the art.
[0044] In the present invention, the mixing preferably further includes a cross-linking reaction; the cross-linking reaction is preferably physical cross-linking, chemical cross-linking, thermal cross-linking or photo cross-linking.
[0045] In the present invention, when the nano delivery carrier is a lipid polymer nanoparticle, the method for preparing the drug-loaded nano preparation comprises the following steps:
[0046] The active ingredient, lipid raw material, polymer raw material, organic solvent and water are mixed to obtain the drug-loaded nano preparation.
[0047] In the present invention, the mass ratio of the active ingredient, the polymer raw material and the lipid raw material is preferably 2:0.67-4:1.33-8, more preferably 2:1-3:2-5, and most preferably 2:1:2; the lipid raw material serves as an amphiphilic lipid material to encapsulate the hydrophobic drug; the polymer raw material serves as an amphiphilic polymer as the core of the nanoparticles to increase the stability of the formed nanoparticles.
[0048] In the present invention, the organic solvent is preferably tetrahydrofuran or N,N-dimethylformamide, more preferably tetrahydrofuran; the mass ratio of the active ingredient to the volume ratio of the organic solvent is preferably 1 mg: 0.267-0.8 mL, more preferably 1 mg: 0.3-0.5 mL, most preferably 1 mg: 0.3 mL; the volume ratio of the organic solvent to water is preferably 1:5-15, more preferably 1:5-10, most preferably 1:5.
[0049] In the present invention, the mixing is preferably vortex mixing, and the time is preferably 1 to 5 minutes, more preferably 3 to 5 minutes; the mixing also preferably includes removing the organic solvent and concentrating; the removal of the organic solvent is preferably adding an equal volume of PBS; the concentration is preferably ultrafiltration concentration.
[0050] In the present invention, the drug-loaded nanoformulation is preferably drug-loaded lipid polymer nanoparticles; the particle size of the drug-loaded lipid polymer nanoparticles is preferably 100-200 nm, more preferably 120-180 nm; the drug-loaded nanoformulation is a drug-loaded nanoformulation dispersion; the concentration of the active ingredient in the drug-loaded nanoformulation dispersion is 1-2 mg / mL; the storage temperature of the drug-loaded nanoformulation dispersion is preferably 4°C.
[0051] In the present invention, the preparation method preferably comprises the following steps:
[0052] Mixing hyaluronic acid, dopamine, a grafting catalyst and water, and performing a grafting reaction in an acidic environment to obtain the hyaluronic acid-dopamine graft;
[0053] The drug-loaded nano preparation, hyaluronic acid-dopamine graft and ammonia water are mixed and cross-linked to obtain the elemene hydrogel.
[0054] The present invention mixes hyaluronic acid, dopamine, a grafting catalyst and water, and performs a grafting reaction in an acidic environment to obtain the hyaluronic acid-dopamine graft.
[0055] In the present invention, the mass ratio of the hyaluronic acid to dopamine is preferably 1:0.404-0.808, more preferably 1:0.5-0.808, and most preferably 1:0.808; the catalyst is preferably 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and N-hydroxysuccinimide; the mass ratio of the hyaluronic acid to 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride is preferably 1:0.273-0.547, more preferably 1:0.35-0.547, most preferably 1:0.547; the mass ratio of the hyaluronic acid to N-hydroxysuccinimide is preferably 1:0.172-0.344, more preferably 1:0.25-0.344, most preferably 1:0.344; in the present invention, the role of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and N-hydroxysuccinimide is to act as catalysts for the grafting (amide) reaction to activate -COOH on the hyaluronic acid. The mass ratio of the hyaluronic acid to the volume of water is 1g:50-200mL, more preferably 1g:50-150mL, most preferably 1g:100mL.
[0056] In the present invention, the feeding order of the grafting reaction is preferably: first dissolving hyaluronic acid in water, then adding the grafting catalyst and stirring, and finally adding dopamine; the stirring time is preferably 15 to 20 minutes; the grafting reaction time is preferably 12 to 24 hours, more preferably 12 to 18 hours, and most preferably 12 hours; the pH value is preferably 5 to 5.5; the pH regulating agent is preferably 1M hydrochloric acid; the grafting reaction also preferably includes dialysis and drying; the dialysis includes acid solution dialysis and water dialysis performed in sequence; the pH of the acid solution dialysis is preferably 5 to 5.5, more preferably 5; the time is preferably 24 to 48 hours, more preferably 24 to 36 hours, and most preferably 48 hours; the water dialysis time is preferably 12 to 24 hours, more preferably 18 to 24 hours, and most preferably 24 hours; the drying is preferably freeze-drying.
[0057] After obtaining the hyaluronic acid-dopamine graft, the present invention mixes the drug-loaded nano preparation, the hyaluronic acid-dopamine graft and a cross-linking agent to perform a cross-linking reaction to obtain the elemene hydrogel.
[0058] In the present invention, the drug-loaded nanoformulation is preferably a drug-loaded nanoformulation dispersion; the volume ratio of the drug-loaded nanoformulation dispersion and the mass ratio of the hyaluronic acid-dopamine graft is preferably 1 mL:10-40 mg, more preferably 1 mL:25-40 mg, and most preferably 1 mL:40 mg; the mass ratio of the hyaluronic acid-dopamine graft and the obtained elemene hydrogel is preferably 1-7.5%:1, more preferably 2-4%:1; the cross-linking agent is preferably ammonia water; the concentration of the ammonia water is preferably 25-28%, more preferably 25%; the volume ratio of the drug-loaded nanoformulation dispersion and ammonia water is preferably 1:0.01-0.03, more preferably 1:0.01; the temperature of the cross-linking reaction is room temperature; the time is preferably 12-24h, more preferably 18-24h.
[0059] The hyaluronic acid-dopamine (HA-DA) graft synthesized by the preparation method provided by the present invention will undergo oxidation (mainly oxidation of dopamine) under alkaline conditions at room temperature, thereby generating covalent bonds between HA-DA polymer chains to cross-link them, thereby forming a hydrogel preparation with a certain shape.
[0060] The present invention also provides the use of the elemene hydrogel described in the above technical solution or the elemene hydrogel obtained by the preparation method described in the above technical solution in preparing a preparation for treating postoperative tumor recurrence or metastasis.
[0061] In the present invention, the tumor includes lung cancer, brain cancer, liver cancer, breast cancer, gastric cancer, esophageal cancer or pancreatic cancer; the application method of the elemene hydrogel is implantation into the resection site after surgery; the present invention does not have any special limitation on the application process of the elemene hydrogel in the preparation of a preparation for treating postoperative tumor recurrence or metastasis, and a method familiar to those skilled in the art can be used.
[0062] In order to further illustrate the present invention, the elemene hydrogel provided by the present invention and its preparation method and application are described in detail below in conjunction with the accompanying drawings and examples, but they should not be construed as limiting the scope of protection of the present invention.
[0063] Example 1
[0064] (1) Preparation of elemene lipid polymer nanoparticles (ELE@LPNPs):
[0065] The lipid polymer nanoparticles used in this embodiment to deliver elemene have better stability and can effectively reduce the volatilization of elemene. After loading elemene into nanoparticles, the hydrophobicity problem of elemene is effectively avoided, and it is beneficial to the subsequent preparation of elemene hydrogel.
[0066] 1 mg of elemene, 0.5 mg of polylactic acid-co-glycolic acid (PLGA), and 1 mg of 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-polyethylene glycol (DSPE-PEG) were dissolved in 0.3 mL of tetrahydrofuran solution and mixed evenly. Then, it was quickly injected into 5 times the volume of pure water and kept vortexed for 3 minutes, and then an equal volume of PBS was added for dialysis to remove the organic solvent in the system. Finally, the obtained elemene nanoparticle dispersion was concentrated by ultrafiltration and stored in a refrigerator at 4°C for use.
[0067] (2) Synthesis of hyaluronic acid-dopamine grafts
[0068] Single hyaluronic acid cannot form hydrogel, so hyaluronic acid needs to be grafted through chemical reaction so that it can form a three-dimensional network structure in the cross-linking agent and become a hydrogel with certain mechanical strength.
[0069] Weigh 1.0g of hyaluronic acid and dissolve it in 100mL pure water. After fully dissolving, transfer it to a three-necked bottle filled with nitrogen, then add 547mg of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) and 344mg of N-hydroxysuccinimide (NHS). After stirring for 20 minutes, add 808mg of dopamine to the above three-necked bottle. 1M hydrochloric acid solution adjusts the pH value to between 5.0 and 5.5 and stirs for 12 hours. After the reaction is completed, transfer the reaction solution to a dialysis bag and dialyze it in an aqueous solution of pH=5 for 48 hours, then dialyze it in pure water for 24 hours, and obtain it after freeze-drying.
[0070] (3) Preparation of elemene hydrogel (ELE@LPNPs@Gel)
[0071] Based on the characteristics of dopamine's self-oxidation in an alkaline environment, ammonia water is used as a cross-linking agent to promote the hyaluronic acid-dopamine graft to form a hydrogel with a three-dimensional network structure in the air.
[0072] Weigh the hyaluronic acid-dopamine graft and completely dissolve it in the elemene lipid polymer nanoparticle dispersion at a volume ratio of 40 mg:1 mL, so that the mass fraction of the gel matrix is 4%. Then add 1% volume of ammonia solution and cross-link at room temperature for 24 hours until the hydrogel turns brown-black to obtain elemene hydrogel.
[0073] Example 2
[0074] The elemene hydrogel was prepared according to the technical scheme provided in Example 1, except that the mass fraction of the gel matrix was 3%.
[0075] Example 3
[0076] The elemene hydrogel was prepared according to the technical scheme provided in Example 1, except that the mass fraction of the gel matrix was 2%.
[0077] Example 4
[0078] The elemene hydrogel was prepared according to the technical scheme provided in Example 1, except that elemene, poly(lactic acid-co-glycolic acid) (PLGA), and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-polyethylene glycol were as shown in Table 1, and the encapsulation efficiency and drug loading of the obtained elemene nanoparticles were tested.
[0079] Table 1 Encapsulation efficiency and drug loading data of elemene nanoparticles obtained in Example 4
[0080]
[0081]
[0082] As shown in Table 1, formulations 1-8 all showed good elemene encapsulation efficiency, but formulation 9 had the lowest encapsulation efficiency, which may be due to the lowest proportion of polymer in the formulation, resulting in a lower elemene encapsulation rate. High encapsulation efficiency and drug loading as well as smaller particle size are conducive to the application of nanomedicine in biomedicine. Therefore, after comprehensive consideration, the product obtained under the condition of a 2:1:2 ratio of the three was selected as a representative elemene nanomedicine for subsequent testing.
[0083] Comparative Example 1
[0084] The elemene hydrogel was prepared according to the technical scheme provided in Example 1, except that the obtained elemene nanoparticle dispersion was directly diluted, and the concentration of elemene nanoparticles in the obtained dispersion was the same as that in the hydrogel obtained in Example 1.
[0085] The test method and equipment used in the test example of the present invention include:
[0086] (1) Dynamic light scattering (DLS) characterization:
[0087] The dispersion of elemene nanoparticles was measured using a scattering angle of 90° C. using a Zetasizer from Malvern Panalytical, and the total concentration of the sample was maintained within a range of 0.1 to 5.0 mg / mL.
[0088] (2) Transmission electron microscopy (TEM) imaging:
[0089] Test instrument: JEOL-2100 transmission electron microscope; Test conditions: 120KV, 101μA; The nanoparticles to be tested are dispersed in water for testing.
[0090] (3) Scanning electron microscope (SEM) imaging
[0091] Test instrument: Sigma 500 scanning electron microscope; Test conditions: 3KV, WD=5.4mm; Samples were tested after freeze-drying.
[0092] (4) Rheological test
[0093] Test instrument: DHR-2 rheometer, test conditions: storage modulus (G') and loss modulus (G") were measured at a strain value of 1%-800% and an angular frequency of 1 rad / s, and the hydrogel sample was prepared into a 25 mm disc.
[0094] (5) Small Animal In Vivo Imaging
[0095] Test instrument: PHOTON IMAGERTM OPTIMA in vivo imager.
[0096] (6) Immune cell phenotype detection
[0097] Test instrument: BD LSRFortessa analytical flow cytometer.
[0098] Test Example 1
[0099] The elemene nanoparticles obtained in Example 1 were characterized, and the results are shown in Figure 1 , wherein A is a physical image of the dispersion of elemene nanoparticle solution, B is a particle size test data image of elemene nanoparticles, C is a Zeta potential test image of elemene nanoparticles, D is a SEM imaging image of elemene nanoparticles, E is an infrared spectrum image of each substance involved in the embodiment, F is a particle size and polydispersity index image of elemene nanoparticles at 37°C, and G is a particle size and polydispersity index image of elemene nanoparticles at 4°C.
[0100] Depend on Figure 1 It can be seen that the elemene lipid polymer nanoparticle solution obtained in Example 1 presents a white colloidal solution with opalescence ( Figure 1 A), the average particle size of the nanoparticles determined by DLS was 182±3.42nm ( Figure 1 B), the average Zeta potential was -41.82±2.45mV ( Figure 1 C); TEM imaging shows that the microscopic morphology of elemene nanoparticles is a round sphere ( Figure 1 D) and has a distinct core-shell structure; Fourier transform infrared spectroscopy further confirmed that elemene was encapsulated in the nanoparticles rather than simply mixed with the encapsulating material ( Figure 1 E). At the same time, elemene nanoparticles have good stability at 4°C and 37°C ( Figure 1 FG).
[0101] Test Example 2
[0102] The elemene hydrogel obtained in Example 1 was characterized, and the results are shown in Figure 2 , wherein A is a schematic diagram of the preparation of elemene hydrogel, B is a nuclear magnetic resonance hydrogen spectrum of hyaluronic acid, dopamine and hyaluronic acid-dopamine grafts, C is a physical picture of elemene hydrogel, D is a characterization diagram of the bioadhesion of elemene hydrogel, E is a SEM imaging diagram of elemene hydrogel, F is a characterization diagram of the self-healing properties of elemene hydrogel, G is a swelling rate test diagram of elemene hydrogel, H is a storage modulus and loss modulus diagram of elemene hydrogel at different angular frequencies, I is a storage modulus and loss modulus diagram of elemene hydrogel under different strains, and J is a cyclic storage modulus and loss modulus value diagram of elemene hydrogel under alternating strain scanning.
[0103] Depend on Figure 2 It can be seen that in Example 1, the elemene nano-solution and the hyaluronic acid-dopamine graft were mixed and then cross-linked in ammonia water to form the elemene hydrogel ( Figure 2 A). Nuclear magnetic resonance spectroscopy proved that the hyaluronic acid-dopamine graft was successfully synthesized ( Figure 2 B), the prepared elemene hydrogel is brownish black ( Figure 2 C), has good biological tissue adhesion ( Figure 2 D), SEM imaging shows that elemene hydrogel presents a porous network structure ( Figure 2 E), has good self-healing properties ( Figure 2 F). In addition, the swelling ratio of elemene hydrogel is about 150% ( Figure 2 G), elemene hydrogel has good mechanical properties at different angular frequencies and strains ( Figure 2 HJ).
[0104] Test Example 3
[0105] To investigate the in vitro release behavior of elemene hydrogel, the hydrogel was placed in a 50 mL centrifuge tube containing 15 mL PBS, and 0.5% Tween-80 and 50 U / mL hyaluronidase were added to the release medium. The centrifuge tube was then placed in a 37°C incubator and shaken slowly. At a predetermined time point, 0.5 mL of the release medium was taken out, and the elemene content was determined by UPLC, and an equal volume of fresh release medium was added.
[0106] To further explore the release of elemene hydrogel in vivo, DiR was used to label ELE@LPNPs and ELE@LPNPs@Gel. After subcutaneous administration of the two elemene preparations obtained in Example 1 and Comparative Example 1 (equal doses of DiR), the fluorescence imaging of mice within 20 days was detected by the small animal in vivo imaging system. In order to more accurately compare the difference in the release effects of the two, coumarin-6-labeled ELE@LPNPs and ELE@LPNPs@Gel were used to study the release and penetration behavior of elemene in tumors. Tumors were collected after 20 days of treatment with the two elemene preparations, and observed under a fluorescence microscope after frozen sections. The results are shown in Figure 3 , wherein A is a schematic diagram of the preparation of elemene hydrogel and elemene nanoparticle dispersion, B is a schematic diagram of the release kinetics of elemene hydrogels at three different concentrations, C is a schematic diagram of the release behavior of elemene hydrogel and elemene nanoparticle dispersion at the mouse level, D is a fluorescent IVIS imaging diagram at different time points after mice were implanted with elemene hydrogel and injected with elemene nanoparticle dispersion using DiR as a fluorescent marker, E is a quantitative data diagram of the residual fluorescence percentage of Figure D after normalization with the fluorescence intensity at the initial time, and F is a fluorescent imaging diagram of the surrounding tissue 20 days after implantation of elemene hydrogel and elemene nanoparticle dispersion.
[0107] Depend on Figure 3 It can be seen that when the prepared elemene hydrogel is placed in a medium, the hydrogel swells due to water absorption, causing the three-dimensional network diffusion barrier of the polymer to loosen, which will cause the elemene nanoparticles loaded in the hydrogel to diffuse into the medium; due to the existence of the diffusion barrier, the release rate of elemene nanoparticles from the hydrogel to the medium is slow, that is, "controlled release". In contrast, when the elemene nanosolution is directly added to the medium, they diffuse rapidly, that is, "instant release" ( Figure 3 A). By changing the concentration of the hydrogel, the diffusion barrier of the hydrogel can be adjusted, the pore size of the hydrogel network can be changed, and thus the diffusion rate of the load can be adjusted. Three concentrations of elemene hydrogels were prepared and subjected to in vitro release experiments, which showed different release kinetics ( Figure 3 B).
[0108] In addition, the sustained release behavior of elemene hydrogel at the mouse level was studied by using the co-loaded near-infrared fluorescent dye DiR as a marker ( Figure 3 C). The elemene in the hydrogel formulation remained at the subcutaneous implant site for up to 20 days, showing significant signal strength. In contrast, the elemene nanoformulation only lasted until day 12 ( Figure 3 In the elemene nanosolution group, almost no elemene nanoparticles were observed in the tissue at the implantation site (green channel), while for the elemene hydrogel group, obvious fluorescence signals could still be clearly observed in the tissue at the implantation site, indicating that a high abundance of elemene nanoparticles existed in the surrounding tissue ( Figure 3 FG).
[0109] Test Example 4
[0110] Postoperative breast cancer model establishment: Luc-4T1 tumor-bearing mice were randomly divided into 4 groups: (1) PBS group, model control group, mice were given PBS after surgical removal of the tumor; (2) ELE@LPNPs group, mice were given elemene nano solution after surgical removal of the tumor; (3) ELE@LPNPs@Gel group, mice were implanted with elemene hydrogel after surgical removal of the tumor; (4) ELE@LPNPs+Gel group, mice were given elemene nano solution and blank gel after surgical removal of the tumor. The elemene dosage in each group was 350 μg / mouse, and there were 6 mice in each group.
[0111] To investigate the effect of elemene hydrogel implantation after breast cancer surgery on tumor recurrence and metastasis: 20 days after administration, tumor tissues and lungs of mice in each group were collected for section staining to detect lung metastasis after breast cancer surgery. In addition, during the experiment, luciferin sodium salt was injected to measure the bioluminescence and tumor volume of mice to detect tumor recurrence, and the weight of mice was recorded at the same time. Results are shown in Figure 4 , wherein A is a schematic diagram of the surgical process of elemene hydrogel inhibiting tumor recurrence and metastasis, B is a timeline diagram of the experiment for inhibiting tumor recurrence and metastasis, C is a bioluminescence imaging diagram of 4T1-Luc tumor-bearing mice after different treatments, D is a bioluminescence quantitative data diagram of Figure C, E is a diagram of the changes in tumor volume of each group of mice after different treatments, F is a representative photograph of mouse lung tissue after different treatments and the corresponding H&E staining image diagram, G is a representative immunohistochemical staining image diagram of E-cadherin in residual tumor tissues after different treatments, and H is a diagram of the changes in weight of mice in each treatment group.
[0112] Depend on Figure 4 It can be seen that luciferase-labeled 4T1 cells were subcutaneously inoculated into Balb / c mice. Eight days later, most of the tumor was surgically removed, leaving a small amount of residual tumor to simulate the tumor residual after surgery in clinical practice ( Figure 4 AB). Then different elemene preparations were given to the residual tumor sites, and the recurrence of the residual tumor was monitored. After treatment, the tumor recurrence rates of the three groups were 25 times (PBS), 8.6 times (ELE@LPNPs), and 1.0 times (ELE@LPNPs@Gel) ( Figure 4 CD), tumor volume measurement results further proved that elemene hydrogel has a more significant effect in inhibiting tumor recurrence ( Figure 4 E), these results indicate that elemene hydrogel has a significant effect in inhibiting tumor recurrence.
[0113] In addition, we also tested the inhibitory effect of elemene hydrogel on tumor metastasis. A large number of tumor-like metastases appeared in the lung tissue of the PBS control group ( Figure 4 F); Compared with elemene nanosolution, elemene hydrogel significantly inhibited breast cancer lung metastasis. The high expression of E-cadherin in the elemene hydrogel treatment group further confirmed that the elemene hydrogel had a stronger inhibitory effect on tumor metastasis than the elemene nanosolution ( Figure 4 G). In addition, during the administration period, the body weight of the mice did not decrease significantly, indicating that the elemene hydrogel has good biocompatibility ( Figure 4 H).
[0114] Test Example 5
[0115] Test on the effect of elemene hydrogel implantation on immune cells in tumor tissue after breast cancer surgery: 20 4T1 tumor-bearing mice were divided into five groups, namely PBS group, ELE@LPNPs group, ELE@LPNPs@Gel group, ELE@LPNPs+Gel group and elemene nano solution group (ELE@LPNPs Fract. group) administered with divided doses. After 20 days of treatment, the tumor tissues of mice in each group were collected and lysed into single cell suspensions. After flow cytometry antibody staining, the proportions of various immune cells in the tumor tissues of mice in each group were determined. At the same time, the serum of mice in each group was collected, and the levels of various anti-tumor factors in the serum were determined by ELISA. The results are shown in the figure. Figure 5 , where A is CD3 after different treatments + CD8 + Representative flow cytometry analysis of T cells, B is CD45 + CD3 + CD8 + Quantitative graph of the percentage of cells, C is the CD45 + CD3 + CD8 + Quantitative graph of the percentage of cells, D is the CD3 + CD4 + Representative flow cytometry analysis of T cells, E is CD45 + CD3 + CD4 + Quantitative graph of the percentage of cells, F is the CD45 + CD3 + CD4 + Quantitative graph of the percentage of cells, G is the CD25 + Foxp3 + Representative flow cytometry analysis of T cells, H is CD4 + CD25 + Foxp3 + Quantitative graph of the percentage of T cells, I is CD25 in tumor cells + Foxp3 +Quantitative graph of the percentage of cells, J is the immunofluorescence image of the residual tumor tissue in different treatment groups. Red: macrophages stained with F4 / 80 antibody; yellow: M1 macrophages stained with CD80 antibody; blue: cell nuclei stained with DAPI. The scale is 40 μm. The secretion levels of inflammatory factors TNF-α (K), IL-6 (L), and IFN-γ (M) in the serum of mice in each group.
[0116] Depend on Figure 5 It can be seen that flow cytometry analysis of the immune cell populations in the residual tumor tissues of each group after 20 days of different treatments. After ELE@LPNPs@Gel treatment, the number of cytotoxic T cells (CD8+ cells) in the residual tumor increased significantly, which was 4.2 times that of the ELE@LPNPs treatment group ( Figure 5 AC). CD4 + The cells are helper T cells. After ELE@LPNPs@Gel treatment, CD4 + The number of cells also increased significantly, 7.5 times that of the ELE@LPNPs-treated group ( Figure 5 DF). In addition, the proportion of regulatory T cells (a type of immunosuppressive immune cell) was significantly reduced after ELE@LPNPs@Gel treatment, which was reduced by 55% compared with the ELE@LPNPs treatment group ( Figure 5 GI).
[0117] M1 macrophages are a type of tumor-associated macrophages, and the increase in their number is beneficial to further clear the residual tumor after surgery. The abundance of M1 macrophages in the residual tumor tissue after different treatments was observed by immunofluorescence imaging. The residual tumor tissue treated with ELE@LPNPs@Gel (Group III) showed obvious green (marked with F4 / 80) and red fluorescence (marked with CD80), which turned yellow after synthesis (marked with M1 macrophages), indicating that the abundance of M1 macrophages was enhanced compared with that treated with ELE@LPNPs (Group II). Figure 5 J).
[0118] The levels of serum anti-tumor immune-related inflammatory factors were determined by ELISA. Compared with the ELE@LPNPs group, ELE@LPNPs@Gel significantly increased the levels of TNF-α, IL-6, and IFN-γ in serum ( Figure 5 KM). The above results all prove that ELE@LPNPs@Gel can promote anti-tumor immune response better than ELE@LPNPs. The results of ELE@LPNPs+Gel group are similar to those of ELE@LPNPs group, which excludes the influence of hydrogel itself on anti-tumor immune response ( Figure 5AM). In addition, ELE@LPNPs Fract. and ELE@LPNPs@Gel have similar effects in regulating T cells, macrophages, and the levels of various pro-inflammatory factors in serum.
[0119] Test Example 6
[0120] Safety evaluation test of elemene hydrogel: Since the elemene hydrogel involved in the present invention is used for in vivo implantation, it is very important to evaluate its safety. First, an in vitro safety study was conducted using L929 cells. The elemene hydrogel extract of different concentrations was co-incubated with the above cells and the cell metabolic activity was measured. At the same time, the whole blood was collected for examination after 30 days of implantation of the elemene hydrogel in healthy mice, and various organs were collected for H&E staining to observe the in vivo safety of elemene. The results are shown in Figure 6 Among them, A is a physical comparison diagram of the hemolysis of elemene hydrogel, B is a diagram of the hemolysis test results of elemene hydrogel, C is a schematic diagram of extracting elemene hydrogel extract, D is a diagram of cell viability after co-incubation of L929 cells with hydrogel extracts of different concentrations for 24 hours, E is a diagram of the changes in various blood biochemical indicators in blood samples of mice treated with elemene hydrogel for 30 days (with untreated healthy mice as the control group), and F is a H&E staining diagram of the five internal organs of healthy mice and mice treated with elemene hydrogel for 30 days.
[0121] Depend on Figure 6 It can be seen that since the elemene hydrogel in this embodiment is used for in vivo implantation, its safety needs to be evaluated. First, the blood compatibility of the elemene hydrogel was evaluated by a hemolysis test. The results showed that the hemolysis rate of the elemene hydrogel was 3.5%, indicating that the elemene hydrogel has good blood compatibility ( Figure 6 AB). After incubating L929 cells with different concentrations of elemene hydrogel extract (62.5-500 μg / mL) for 24 hours, there was no significant change in cell viability compared with the control group ( Figure 6 CD). After 30 days of implantation of elemene hydrogel into healthy mice, blood biochemical parameters were measured in blood samples, and major organs were collected for hematoxylin-eosin staining. Compared with normal healthy mice, elemene hydrogel treatment had a significant effect on the blood ( Figure 6 E) and organs ( Figure 6 F) No significant effect. The results showed that elemene hydrogel has good biosafety.
[0122] Figure 7 Schematic diagram of the release kinetics of elemene nanoformulation controlled by hydrogel, wherein A is a schematic diagram of the release kinetics of elemene hydrogel and elemene nano solution, and B is a diagram showing the mechanism of hydrogel with controlled elemene nanodrug release kinetics inhibiting postoperative recurrence and metastasis of breast cancer.
[0123] According to the above embodiments, test examples and Figure 7 It can be seen that ELE hydrogel (ELE@LPNPs@Gel), compared with ELE nanodrug droplets, showed controlled release kinetics of ELE in preclinical models and significantly inhibited the recurrence and metastasis of breast cancer. More importantly, this new ELE hydrogel significantly changed the immune microenvironment of the lesion site and increased the number of anti-tumor immune cells and cytokines. These findings highlight the potential of ELE hydrogel to inhibit postoperative cancer recurrence and metastasis by prolonging drug exposure time and enhancing anti-tumor immune response.
[0124] Although the above embodiment describes the present invention in detail, it is only a part of the embodiments of the present invention, not all of the embodiments. People can also obtain other embodiments based on this embodiment without creativity, and these embodiments all fall within the protection scope of the present invention.
Claims
1. An elemene hydrogel, characterized in that: It comprises a hydrogel matrix and a drug-loaded nanoformulation distributed in the hydrogel matrix; the drug-loaded nanoformulation comprises a nano delivery carrier and an effective ingredient loaded in the nano delivery carrier; the effective ingredient comprises β-elemene, elemene raw material drug or a drug pair containing elemene.
2. The elemene hydrogel according to claim 1, characterized in that The drug pair containing elemene includes elemene-cabazitaxel, elemene-oxaliplatin, elemene-sorafenib or elemene-cisplatin.
3. The elemene hydrogel according to claim 1, characterized in that The nano-delivery carrier includes liposomes, lipid nanoparticles, polymer nanoparticles, lipid polymer nanoparticles, nanoemulsions, mesoporous silica or nanosheets; The raw materials for preparing the lipid polymer nanoparticles include lipid raw materials and polymer raw materials; the lipid raw materials of the lipid polymer nanoparticles include 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-polyethylene glycol or dimyristoylglycerol-polyethylene glycol, and the polymer raw materials include polylactic acid-co-glycolic acid, polylactic acid or polyacetic acid lactone; The nanosheets include stanene nanosheets or germanene nanosheets.
4. The elemene hydrogel according to claim 1, characterized in that The raw materials for preparing the hydrogel matrix include gel matrix materials; the gel matrix materials include one or more of polyethylene glycol, methacrylic acid, hyaluronic acid-dopamine grafts, chitosan, alginate and silk fibroin; The grafting degree of the hyaluronic acid-dopamine graft is 30-70%.
5. The elemene hydrogel according to claim 1, characterized in that The particle size of the drug-loaded nanoparticle preparation is 20 to 500 nm; The concentration of the drug-loaded nanometer preparation in the elemene hydrogel is 5-20 mg / mL, the concentration of the effective component is 1-4 mg / mL, and the water content is 92-98%.
6. The method for preparing the elemene hydrogel according to any one of claims 1 to 5, characterized in that: The following steps are involved: Constructing a drug-loaded nanoformulation, wherein the drug-loaded nanoformulation comprises a nano delivery carrier and an effective ingredient loaded in the nano delivery carrier; The drug-loaded nanoformulation and the gel matrix material are mixed to obtain the elemene hydrogel.
7. The preparation method according to claim 6, characterized in that: When the nano delivery carrier is a lipid polymer nanoparticle, the preparation method of the drug-loaded nano preparation comprises the following steps: The active ingredient, lipid raw material, polymer raw material, organic solvent and water are mixed to obtain the drug-loaded nano preparation.
8. The preparation method according to claim 6, characterized in that: The preparation method of the hyaluronic acid-dopamine graft comprises the following steps: Hyaluronic acid, dopamine, a grafting catalyst and water are mixed, and a grafting reaction is carried out in an acidic environment to obtain the hyaluronic acid-dopamine grafted product.
9. Use of the elemene hydrogel according to any one of claims 1 to 5 or the elemene hydrogel obtained by the preparation method according to any one of claims 6 to 8 in preparing a preparation for treating postoperative tumor recurrence or metastasis.
10. The use according to claim 9, characterized in that: The tumor includes lung cancer, brain cancer, liver cancer, breast cancer, stomach cancer, esophageal cancer or pancreatic cancer.
Citation Information
Cited By
Graded-loading and in-situ controlled-release nano-composite hydrogel material as well as preparation and application thereof
CN120420266A
